Anzeige
Mehr »
Login
Sonntag, 22.12.2024 Börsentäglich über 12.000 News von 679 internationalen Medien
Breaking News: Vorweihnachtlicher Kaufrausch an der Börse?
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

WKN: A3CR1N | ISIN: KYG1996C1006 | Ticker-Symbol:
Branche
Biotechnologie
Aktienmarkt
ASIEN
1-Jahres-Chart
CARSGEN THERAPEUTICS HOLDINGS LTD Chart 1 Jahr
5-Tage-Chart
CARSGEN THERAPEUTICS HOLDINGS LTD 5-Tage-Chart

Aktuelle News zur CARSGEN THERAPEUTICS Aktie

Aktienalarm. Jetzt kostenlos anmelden!

E-Mail
Aktivieren
  • Alle
  • Pressemitteilungen
  • Empfehlungen
  • Chartanalysen
  • Berichte
ZeitAktuelle Nachrichten
Sprache: Alle DE EN
LeserMedien
11.12.HSI Closes at 20,155, Down 156 pts; HSTI Closes at 4,531, Down 60 pts; HANG LUNG PPT Down over 3%; FOSUN TOURISM, CARSGEN-B, MOBVISTA, SY HOLDINGS, MARKETINGFORCE Hit New Highs; Market Turnover Rises7
10.12.CARSGEN-B (02171): TERMS OF REFERENCE FOR THE AUDIT COMMITTEE2
10.12.CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - UPDATED RESEARCH RESULTS ON ZEVOR-CEL, CT071 AND CT0590 AT ASH 2024 ANNUAL CONGRESS1
18.11.CARSGEN-B (02171): GRANT OF OPTIONS PURSUANT TO THE POST-IPO SHARE OPTION SCHEME-
01.11.CARsgen Therapeutics: CARsgen U.S. Clinical Holds Lifted by FDA54SHANGHAI, Oct. 31, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for...
► Artikel lesen
01.11.CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - LIFT OF THE U.S. CLINICAL HOLDS FOR ZEVORCABTAGENE AUTOLEUCEL, SATRICABTAGENE AUTOLEUCEL AND CT071 BY FDA1
17.10.CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - TO PRESENT ZEVORCABTAGENE AUTOLEUCEL, CT071 AND CT0590 AT ASH 2024 ANNUAL CONGRESS1
CARSGEN THERAPEUTICS Aktie jetzt für 0€ handeln
10.10.China's CARsgen Applies to Resume CAR-T Cell Therapy Trials in US After Passing Reinspection1
09.10.CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - APPLICATION TO REQUEST LIFTING CLINICAL HOLDS SUBMITTED TO FDA1
09.09.CARSGEN-B (02171): INTERIM REPORT 20241
29.08.CARsgen Therapeutics: CARsgen Announces 2024 Interim Results119SHANGHAI, Aug. 29, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies...
► Artikel lesen
28.08.CARSGEN-B (02171): ANNOUNCEMENT OF INTERIM RESULTS FOR THE SIX MONTHS ENDED JUNE 30, 2024-
19.08.CARsgen Therapeutics: CARsgen Announces Enrollment Completion in China GC/GEJ Pivotal Phase II Clinical Trial of the First-in-class Claudin18.2 CAR T (Satri-cel)89SHANGHAI, Aug. 19, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies...
► Artikel lesen
19.08.CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - COMPLETION OF ENROLLMENT OF CONFIRMATORY PHASE II CLINICAL TRIAL OF SATRICABTAGENE AUTOLEUCEL IN CHINA1
15.08.CARSGEN-B (02171): DATE OF BOARD MEETING1
28.06.CARSGEN-B (02171): NEXT DAY DISCLOSURE RETURN-
27.06.CARSGEN-B (02171): VOLUNTARY ANNOUNCEMENT - SHAREHOLDING INCREASE BY THE SUBSTANTIAL SHAREHOLDER AND SHARE REPURCHASE BY THE COMPANY1
15.06.CARsgen Therapeutics: CARsgen Presents First-in-human Results of GPRC5D Targeting CAR-T CT071 at EHA 2024474SHANGHAI, June 15, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies...
► Artikel lesen
29.04.CARsgen Therapeutics: CARsgen Submitted Responses to FDA Observations93SHANGHAI, April 29, 2024 /PRNewswire/ -- CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies...
► Artikel lesen
27.03.CARsgen Therapeutics: CARsgen Announced 2023 Annual Results181SHANGHAI, March 27, 2024 /PRNewswire/ -- March 27, 2024, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic...
► Artikel lesen
Seite:  Weiter >>
21 Nachrichten in den letzten 12 Monaten
Ich würde die Aktie auf Sicht von 6 Monaten
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
1,1,1